Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

By A. Eggermont, C. Blank, M. Mandalà, Georgina V. Long, V. Atkinson, S. Dalle, A. Haydon, M. Lichinitser, A. Khattak, M. Carlino and 19 more. New England Journal of Medicine, 2018

1,561 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/476e676018325cd24dd1f702486f62acf425539d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. D. Pardoll

In Oncology

1. D. Pardoll
2. Janis Taube
3. S. Topalian
4. Lieping Chen
5. Antoni Ribas
6. J. Wolchok
7. M. Smyth
8. Jacques Banchereau

Citations in the corpus

• Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. (2019, methodology): “In addition, pembrolizumab has been evaluated against placebo for stage IIIA (SN >1 mm), B and C (without ITM) within the EORTC 1325 trial [57].”
• Neoadjuvant checkpoint blockade for cancer immunotherapy (2020, background): “In surgically resectable metastatic melanoma (stages IIIA to IV), randomized phase 3 clinical trials demonstrated the efficacy of adjuvant anti– PD-1 therapy, leading the FDA to approve nivolumab and pembrolizumab for this indication (8, 9).”